Akademik Veri Yönetim Sistemi
XXXIII. WASPaLM World Congress & XXIV. National Clinical Biochemistry Congress , Antalya, Türkiye, 16 - 20 Kasım 2024, ss.1, (Özet Bildiri)
The effect of Myrtus communis extract on lncRNA-PVT1 expression in A549 lung cancer
and BEAS-2B normal bronchial cells
Bekircan Demir 1 , Gamze Nur Öter 2,3 , Remzi Okan Akar 4,5,6 , Ali Şen 7 , Canan Küçükgergin 1
1 Istanbul University, Istanbul Faculty of Medicine, Department of Medical Biochemistry
2 Istanbul University, Institute of Health Sciences, Department of Medical Biochemistry
3 Istinye University, Faculty of Medicine, Department of Medical Pathology
4 Istinye University, Institute of Graduate Education, Department of Molecular Oncology
5 Istinye University, Faculty of Medicine, Department of Medical Biochemistry
6 Moleculer Cancer Research Center, Istinye University
7 Marmara University, Faculty of Pharmacy, Department of Pharmacognosy
Objective: Approximately 12.3% of all cancer cases worldwide are lung cancer, making it the
most prevalent type of cancer. Finding sensitive biomarkers that can be utilized as targets
for therapy and for diagnosis has long been a top priority in cancer research. Long non-
coding RNAs (lncRNAs) have been shown in numerous studies to play a role in the
emergence of cancers. One of these lncRNAs, plasmacytoma variant translocation 1 (PVT1),
looks quite interesting and is implicated in several cancers. PVT1 is a long non-coding RNA
that is encoded by the human PVT1 gene. According to recent research, PVT1 expression is
higher in several cancer types as compared to the equivalent neighboring non-tumor tissues.
While Myrtus communis (MC) has been studied extensively for its medicinal benefits, no
research has looked at how its essential oil and other MC components affect PVT1
expression levels in lung cancer cells, despite MC having a high biological activity.
Material & Method: Myrtus communis leaf ethanol extracts (MCE) were added to cells at
varying concentrations (0.01–1000 μg/ml) and left for a full day at 37 °C. The
Sulforhodamine B (SRB) assay was used to quantify the cytotoxic effect of MCE on A549 and
BEAS-2B cells. Reverse transcriptase polymerase chain reaction (qRT-PCR) was used to
determine the impact of MCE on the level of PVT1 expression in A549 and BEAS-2B cells. A
control group of healthy cells was BEAS-2B cells. 2\deltadeltact was used to evaluate the
PVT1 expression levels.
Results: According to the SRB results, MCE inhibited the proliferation of A549 and BEAS-2B
cells with an IC50 value of 100 μg/ml and 1000 μg/ml, respectively. To compare PVT1
expression analysis, cells were treated with MCE at IC50 and IC25 doses. When MCE was
given to A549 cells, PVT1 expression levels dropped in comparison to the control group. At
the 100 μg/ml MCE dose, this drop was observed 1.67 times; however, no significant
decrease was found. Applying 500 μg/ml MCE to BEAS-2B cells resulted in a 2-fold decrease
in PVT1 expression level when compared to the control, indicating a significant difference.
PVT1 expression level was found to rise 1.85 times compared to the control when the MCE
dose of 100 μg/ml was applied; no discernible difference was found. PVT1 expression levels
were found to be lower in the group that received higher rates of MCE dosage application
for both cell lines than in the group that received lower doses.
Conclusion: This study is an important preliminary study in terms of guiding future studies
and is the first study to examine the effects of MC on PVT1 expression levels in lung cancer
cells. The results show that MC has a significant anti-cancer effect on A549 cancer cells. For
this reason, it is thought that it is important to reveal the compounds responsible for the
effect through future bioactivity-directed fractionation (BAYF) studies, standardize the
extract based on these compounds, and evaluate the effect of the extract with in vivo
studies in order to evaluate the results more accurately.
Keywords: Lung cancer, anti-cancer effect, lncRNA-PVT1, Myrtus communis